Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|December 19, 2024

Pharma Pulse 12/19/24: The Lifespan of Mature Drugs in 2025, Women have a Greater Genetic Risk for PTSD & more

The latest news for pharma industry insiders.

The Lifespan of Mature Drugs in 2025: Q&A with Kirsten Jacobs

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs.

Women have a Greater Genetic Risk for PTSD

Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the first time that women have a great inherited biological risk.

Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Wisp Partners with Nourish to Offer Patients on GLP-1s Personalized Nutrition Counseling

Wisp announced a strategic partnership with Nourish. Wisp patients can now access nutrition counseling services either through their health insurance or an exclusive self-pay rate, making it easier for women seeking a more holistic approach to weight management to access high-quality nutrition support at an affordable price.

Nicholas Saraceno on LinkedIn

Thank you for the educational chat, Vibhu Tewary. A real pleasure!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.